Ferring Pharmaceuticals Receives U.S. FDA Approval for Manufacturing Scale-up Process of Gene Therapy ADSTILADRIN®

Ferring Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for its ADSTILADRIN intravesical gene therapy manufacturing process. The drug is used to treat non-muscle invasive bladder cancer in adult patients with high-risk Bacillus Calmette-Guérin-unresponsive carcinoma in situ with or without papillary tumors. Ferring intends to make ADSTILADRIN available as p..